We take no money from the companies we review: no ads, no affiliate links, no sponsorships. Our editorial independence

HomeTrials › NCT07701460

Obesity & weight · Not applicable · Opening soon

Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1

NCT07701460 · Sponsor: Tufts University

What this trial means for you

This study is opening soon at 1 US site. It's studying see the official record for weight maintenance.

Who can joinAll sexes, 18 Years and older
Healthy volunteersNo, diagnosis required
What you'd takesee the official record
Study length~18 months overall
Planned participants200
TypeInterventional (you receive treatment)

What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study, ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.

The study, in the sponsor's words

Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Researchers at Tufts University are conducting a study to learn whether a digital lifestyle program can help people maintain their weight loss after they stop taking a GLP-1 medication. Adults who have recently stopped a GLP-1 medication may be eligible to participate. Participants will be randomly assigned to either receive access to a digital program or to continue with usual care. The study lasts 12 months and is fully remote. All participants will receive a Bluetooth scale to track weight from home and will complete short online questionnaires several times over the year. By taking part, participants can help researchers better understand how to support long-term weight maintenance in a way that is affordable, accessible, and sustainable. Participants are compensated for their time, and involvement may help improve care for others with similar experiences.

Can you join? The exact criteria

Below is the verbatim eligibility text from the registry. Bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.

Full eligibility criteria (for you and your doctor)

Inclusion Criteria: * 18 years of age or older (no upper limit); * ability to read, write, and speak English and/or Spanish; * ability to provide informed consent; * less than 30-days since GLP-1 RA cessation; * willing to participate. Exclusion Criteria: * No clinically significant weight loss (e.g., \< 5% body weight) while taking GLP medication; * major psychiatric illness, cognitive impairment, or substance misuse that could impair ability to participate; * medical conditions that significantly affect weight or make participation unsafe (e.g., pregnancy or breastfeeding, recent bariatric surgery, current use of GLP 1 or other anti-obesity medications, or endocrine disorders that alter weight regulation); * inability to use a smartphone or complete remote study procedures; * participation in another weight loss or maintenance program or clinical trial judged by investigators to interfere with study involvement; * Adults unable to consent (cognitively impaired); * Wards of the state; * Anyone under age 18.

Study sites by state

Massachusetts

  • This study is conducted remotely, Boston

View the official record on ClinicalTrials.gov →

Verify before you act. Medical disclaimer: content on this site is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs; always consult a licensed healthcare provider about eligibility, risks, and benefits. Trial details and enrollment status change frequently, so always verify on the official registry and talk to your own clinician before contacting a study site. This page was generated from registry data and is not affiliated with the study sponsor.

Follow this trial

Get an email when our monthly digest covers enrollment changes and results for trials like this one.

Keep researching on StudyBackedHealth